Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REPLIGEN CORPORATION

(RGEN)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 12/03 02:14:17 pm
261.54 USD   -2.71%
11/22INSIDER SELL : Repligen
MT
11/17REPLIGEN CORPORATION : Technically solid
11/15INSIDER SELL : Repligen
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Repligen : Announces Agreement to Acquire Avitide Inc (Form 8-K)

09/16/2021 | 08:02am EST

Repligen Announces Agreement to Acquire Avitide Inc.

Proposed acquisition strengthens Repligen's Proteins business

Adds a market leader in affinity ligand discovery and development and complements established partnership with Navigo GmbH

Strategically moves Repligen into affinity resin solutions for gene therapy

Avitide is expected to contribute approximately $10 million in revenue in 2022 and be accretive to Repligen's adjusted earnings per share in 2023

WALTHAM, MA - September 16, 2021 - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held Avitide Inc., for approximately $150 million, comprised of $75 million in cash plus $75 million in Repligen common stock in addition to performance-based earnout payments over the next three years. Avitide is a leading chromatography developer with diverse affinity ligand libraries and best-in-classligand-to-resin development timelines.

Tony J. Hunt, President and CEO of Repligen said, 'The addition of Avitide is a major step forward in building out our Proteins business and in particular our affinity ligand discovery engine. This acquisition builds off the excellent partnership we have already established with Navigo GmbH and really strengthens and expands our ligand discovery and development capabilities. We are excited to have the entire Avitide team join Repligen and look forward to accelerating the commercialization of Avitide's discovery platform. Together, we anticipate bringing many new products to market over the coming years, directly addressing the growing need for affinity solutions in gene therapy and other emerging modalities.'

1

Kevin Isett, President and CEO of Avitide said, 'We have made tremendous progress in affinity ligand and chromatography development over the past decade. Avitide's culture of rapid and continuous technology innovation is what differentiates us from other companies and it is where we feel a strong kinship with Repligen. Repligen is the ideal partner to drive the expanded adoption of existing products and introduction of new products to the market through the combination of their established global operational and commercial capabilities and Avitide's unique and differentiated affinity chromatography discovery platform.'

Approvals and Financing

The transaction is expected to be completed during the third quarter of 2021, subject to the satisfaction of customary closing conditions. To fund the transaction, Repligen intends to use its cash on hand, which totaled approximately $734 million at June 30, 2021. Perella Weinberg Partners LP is acting as financial advisor and Goodwin Procter LLP is serving as legal counsel to Repligen. EC M&A is acting as the financial advisor and Morgan, Lewis & Bockius LLP is serving as the legal counsel to Avitide for the transaction.

About Repligen Corporation

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. We are inspiring advances in bioprocessing for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located within the U.S. (California, Massachusetts, New Jersey and New York), and outside of the U.S. we have sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company, including Repligen news releases, see our website at www.repligen.com. Follow us on LinkedIn and Twitter.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, express or implied statements or guidance regarding the expected results of the proposed acquisition of Avitide, Inc. on Repligen's future financial performance, including the accretive nature and the timing of the accretive nature of the acquisition, expected synergies following the acquisition of Avitide, customer adoption of Avitide's products, the expected expansion of Repligen's product lines, the timing of the closing of the acquisition and other statements identified by words like 'believe,' 'expect,' 'anticipate,' 'may,' 'will,' 'should,' 'seek,' or 'could' and similar expressions, constitute

2

forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the risk that the proposed acquisition may not be completed in a timely manner, or at all; the occurrence of any event, change or other circumstance that could give rise to the termination of the acquisition; our ability to integrate Avitide's business and personnel and to achieve expected synergies; our ability to maintain or expand Avitide's historical sales; our ability to accurately forecast the acquisition, related restructuring costs and allocation of the purchase price, goodwill and other intangibles acquisition related and other asset adjustments; and other risks detailed in Repligen's most recent Annual Report on Form 10-K and the most recently filed Quarterly Report on Form-10-Q on file with the Securities and Exchange Commission and the other reports that Repligen periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Repligen contemplated by these forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. These forward-looking statements reflect management's current views and are based only on information currently available to us. Repligen does not undertake to update, whether written or oral, any of these forward-looking statements to reflect a change in its views or events or circumstances, whether as a result of new information or otherwise, that occur after the date hereof except as required by law.

Repligen Contact:

Sondra S. Newman

Global Head of Investor Relations

(781) 419-1881

investors@repligen.com

# # #

3

Disclaimer

Repligen Corporation published this content on 16 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 September 2021 12:01:12 UTC.


ę Publicnow 2021
All news about REPLIGEN CORPORATION
11/22INSIDER SELL : Repligen
MT
11/15INSIDER SELL : Repligen
MT
11/12Repligen Corporation to Present at Upcoming Investor Conferences
GL
11/08Repligen Releases Inaugural Sustainability Report
AQ
11/05Repligen Releases Inaugural Sustainability Report
AQ
11/04INSIDER SELL : Repligen
MT
11/02INSIDER SELL : Repligen
MT
10/29SVB Leerink Adjusts Price Target on Repligen to $325 from $260, Keeps Outperform Rating
MT
10/28REPLIGEN CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
AQ
10/28Repligen Corporation Reports Earnings Results for the Third Quarter and Nine Months End..
CI
More news
Analyst Recommendations on REPLIGEN CORPORATION
More recommendations
Financials (USD)
Sales 2021 664 M - -
Net income 2021 128 M - -
Net cash 2021 431 M - -
P/E ratio 2021 120x
Yield 2021 -
Capitalization 14 863 M 14 863 M -
EV / Sales 2021 21,7x
EV / Sales 2022 18,1x
Nbr of Employees -
Free-Float 93,2%
Chart REPLIGEN CORPORATION
Duration : Period :
Repligen Corporation Technical Analysis Chart | RGEN | US7599161095 | MarketScreener
Technical analysis trends REPLIGEN CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 268,82 $
Average target price 318,11 $
Spread / Average Target 18,3%
EPS Revisions
Managers and Directors
Tony J. Hunt President, Chief Executive Officer & Director
Jon K. Snodgres Chief Financial Officer
Karen A. Dawes Chairman
Ralf Kuriyel Senior Vice President-Research & Development
James R. Bylund Senior Vice President-Global Operations & IT
Sector and Competitors
1st jan.Capi. (M$)
REPLIGEN CORPORATION40.28%14 863
ABBOTT LABORATORIES17.25%227 013
MEDTRONIC PLC-9.96%144 277
BECTON, DICKINSON AND COMPANY-3.42%68 717
HOYA CORPORATION24.39%57 923
DEXCOM, INC.51.53%54 298